Healthcare of Ontario Pension Plan Trust Increases Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Healthcare of Ontario Pension Plan Trust Fund raised its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 318.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission . The institutional investor owned 372,900 shares of the company’s stock after acquiring an additional 283,700 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Dr. Reddy Laboratories were worth $28,411,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. QRG Capital Management Inc. boosted its stake in Dr. Reddy’s Laboratories by 2.3% in the second quarter. QRG Capital Management Inc. now owns 7,910 shares of the company’s stock valued at $603,000 after acquiring an additional 180 shares during the period. Augustine Asset Management Inc. grew its position in Dr. Reddy’s Laboratories by 0.4% in the second quarter. Augustine Asset Management Inc. now owns 50,624 shares of the company’s stock worth $3,857,000 after purchasing an additional 181 shares during the period. Lester Murray Antman dba SimplyRich raised its stake in Dr. Reddy’s Laboratories by 3.1% in the second quarter. Lester Murray Antman dba SimplyRich now owns 6,178 shares of the company’s stock worth $470,000 after buying an additional 184 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Dr. Reddy’s Laboratories by 1.6% in the first quarter. Sequoia Financial Advisors LLC now owns 14,526 shares of the company’s stock valued at $1,065,000 after buying an additional 232 shares during the period. Finally, First Trust Direct Indexing LP boosted its position in shares of Dr. Reddy’s Laboratories by 2.4% in the first quarter. First Trust Direct Indexing LP now owns 10,634 shares of the company’s stock valued at $780,000 after buying an additional 251 shares during the period. 14.02% of shares are held by institutional investors.

Dr. Reddy’s Laboratories stock rose 0.4%

Shares of RDY stock opened at $79.57 on Friday. The firm has a market cap of $13.28 billion, a P/E ratio of 19.74, a P/E/G ratio of 1.75 and a beta of 0.55. Dr. Reddy’s Laboratories Limited has a 12-month low of $63.72 and a 12-month high of $84.46. The firm has a fifty day moving average price of $81.17 and a 200 day moving average price of $75.92. The company has a current ratio of 2.55, a quick ratio of 1.90, and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report ) last posted its earnings results on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The firm had revenue of $919.80 million for the quarter, compared to the consensus estimate of $861.68 million. equities research analysts expect that Dr. Reddy’s Laboratories Limited will post 4.11 earnings per share for the current year.

Analysts on Wall Street are forecasting an increase

Separately, Barclays raised their target price on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th.

Read our latest review of RDY

Dr. Reddy’s Laboratories Company Profile

(Free Report)

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated global pharmaceutical company. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI) and Others segments. The Company’s Global Generics segment manufactures and markets finished prescription and over-the-counter pharmaceutical products that are marketed under a brand name or as generic finished doses with therapeutic equivalence to branded formulations, and engages in the biologics business .

Recommended articles

Want to see what other hedge funds own RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report).

Get daily news and reviews for Dr. Reddy’s Laboratories – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dr. Reddy’s Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.